CY1123793T1 - Γονιδιακη θεραπεια rpgr για μελαγχρωστικη αμφιβληστροειδοπαθεια - Google Patents
Γονιδιακη θεραπεια rpgr για μελαγχρωστικη αμφιβληστροειδοπαθειαInfo
- Publication number
- CY1123793T1 CY1123793T1 CY20211100002T CY211100002T CY1123793T1 CY 1123793 T1 CY1123793 T1 CY 1123793T1 CY 20211100002 T CY20211100002 T CY 20211100002T CY 211100002 T CY211100002 T CY 211100002T CY 1123793 T1 CY1123793 T1 CY 1123793T1
- Authority
- CY
- Cyprus
- Prior art keywords
- rpgr
- melangrosis
- amphiblistroidopathy
- gene therapy
- rpgr gene
- Prior art date
Links
- 101001104102 Homo sapiens X-linked retinitis pigmentosa GTPase regulator Proteins 0.000 title abstract 2
- 102100040092 X-linked retinitis pigmentosa GTPase regulator Human genes 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
- 208000017442 Retinal disease Diseases 0.000 abstract 2
- 206010038923 Retinopathy Diseases 0.000 abstract 2
- 102000013446 GTP Phosphohydrolases Human genes 0.000 abstract 1
- 108091006109 GTPases Proteins 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 102000034356 gene-regulatory proteins Human genes 0.000 abstract 1
- 108091006104 gene-regulatory proteins Proteins 0.000 abstract 1
- 102000050188 human RPGR Human genes 0.000 abstract 1
- 230000004777 loss-of-function mutation Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462028638P | 2014-07-24 | 2014-07-24 | |
| PCT/US2015/040866 WO2016014353A1 (en) | 2014-07-24 | 2015-07-17 | Rpgr gene therapy for retinitis pigmentosa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123793T1 true CY1123793T1 (el) | 2022-05-27 |
Family
ID=55163577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100002T CY1123793T1 (el) | 2014-07-24 | 2021-01-05 | Γονιδιακη θεραπεια rpgr για μελαγχρωστικη αμφιβληστροειδοπαθεια |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10314924B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3191139B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6654760B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107206105A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2991750C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1123793T1 (cg-RX-API-DMAC7.html) |
| DK (2) | DK3191139T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2987090T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3821912T3 (cg-RX-API-DMAC7.html) |
| HR (2) | HRP20241154T1 (cg-RX-API-DMAC7.html) |
| HU (2) | HUE052781T2 (cg-RX-API-DMAC7.html) |
| LT (2) | LT3191139T (cg-RX-API-DMAC7.html) |
| PL (2) | PL3821912T3 (cg-RX-API-DMAC7.html) |
| PT (2) | PT3821912T (cg-RX-API-DMAC7.html) |
| RS (2) | RS61307B1 (cg-RX-API-DMAC7.html) |
| SI (2) | SI3191139T1 (cg-RX-API-DMAC7.html) |
| SM (2) | SMT202400309T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016014353A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE052781T2 (hu) * | 2014-07-24 | 2021-05-28 | Massachusetts Eye & Ear Infirmary | RPGR génterápia a retinitis pigmentosa terápiájára |
| WO2016098078A2 (en) * | 2014-12-19 | 2016-06-23 | Novartis Ag | Dimerization switches and uses thereof |
| EP3268481B1 (en) * | 2015-03-11 | 2020-05-27 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Rpgr vectors for treating x-linked retinitis pigmentosa |
| GB201516066D0 (en) | 2015-09-10 | 2015-10-28 | Young & Co Llp D | Treatment of retinitis pigmentosa |
| GB201704192D0 (en) | 2017-03-16 | 2017-05-03 | Nightstarx Ltd | Treatment of Retinitis Pigmentosa |
| KR102763312B1 (ko) * | 2017-10-20 | 2025-02-07 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 치료적으로 유효한 양의 재조합 aav9- 유도 벡터의 망막하 전달을 포함하는 대상체의 원추 광수용체 내 관심의 폴리뉴클레오티드를 발현하는 방법 |
| DK3710590T3 (da) * | 2017-11-15 | 2024-08-12 | Univ Michigan Regents | Virale vektorer omfattende rdh12-kodende områder og fremgangsmåder til behandling af nethindedystrofier |
| WO2021183779A1 (en) | 2020-03-11 | 2021-09-16 | Massachusetts Eye And Ear Infirmary | Gene therapy for nmnat1-associated retinal degeneration |
| CN120350069A (zh) * | 2024-01-12 | 2025-07-22 | 北京中因科技有限公司 | 视网膜色素变性动物模型及其构建方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| ATE68013T1 (de) | 1985-07-05 | 1991-10-15 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
| WO1989002468A1 (en) | 1987-09-11 | 1989-03-23 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
| WO1989005345A1 (en) | 1987-12-11 | 1989-06-15 | Whitehead Institute For Biomedical Research | Genetic modification of endothelial cells |
| ATE152169T1 (de) | 1988-02-05 | 1997-05-15 | Whitehead Biomedical Inst | Modifizierte hepatozyten und deren anwendung |
| AU656544B2 (en) | 1990-10-31 | 1995-02-09 | Brigham And Women's Hospital | Genetic modification of endothelial cells |
| US5767079A (en) * | 1992-07-08 | 1998-06-16 | Celtrix Pharmaceuticals, Inc. | Method of treating ophthalmic disorders using TGF -β |
| WO2001038578A1 (en) * | 1999-11-24 | 2001-05-31 | Cornell Research Foundation, Inc. | Inherited retinal diseases at the canine rp3 locus: linkage, marker- and mutation-based tests |
| GB0008801D0 (en) * | 2000-04-10 | 2000-05-31 | Medical Res Council | Sequences |
| CN102925445A (zh) * | 2011-08-08 | 2013-02-13 | 刘军 | 一种获得rpgr 基因新的转录剪切形式的方法 |
| EP2872183B1 (en) * | 2012-07-11 | 2018-09-26 | The Trustees Of The University Of Pennsylvania | Aav-mediated gene therapy for rpgr x-linked retinal degeneration |
| GB201412011D0 (en) * | 2014-07-04 | 2014-08-20 | Ucl Business Plc | Treatments |
| HUE052781T2 (hu) * | 2014-07-24 | 2021-05-28 | Massachusetts Eye & Ear Infirmary | RPGR génterápia a retinitis pigmentosa terápiájára |
-
2015
- 2015-07-17 HU HUE15825383A patent/HUE052781T2/hu unknown
- 2015-07-17 JP JP2017525514A patent/JP6654760B2/ja active Active
- 2015-07-17 RS RS20201416A patent/RS61307B1/sr unknown
- 2015-07-17 PT PT201992088T patent/PT3821912T/pt unknown
- 2015-07-17 FI FIEP20199208.8T patent/FI3821912T3/fi active
- 2015-07-17 EP EP15825383.1A patent/EP3191139B1/en active Active
- 2015-07-17 SI SI201531413T patent/SI3191139T1/sl unknown
- 2015-07-17 PL PL20199208.8T patent/PL3821912T3/pl unknown
- 2015-07-17 LT LTEP15825383.1T patent/LT3191139T/lt unknown
- 2015-07-17 SI SI201532022T patent/SI3821912T1/sl unknown
- 2015-07-17 EP EP20199208.8A patent/EP3821912B1/en active Active
- 2015-07-17 DK DK15825383.1T patent/DK3191139T3/da active
- 2015-07-17 PT PT158253831T patent/PT3191139T/pt unknown
- 2015-07-17 SM SM20240309T patent/SMT202400309T1/it unknown
- 2015-07-17 US US15/328,617 patent/US10314924B2/en active Active
- 2015-07-17 PL PL15825383T patent/PL3191139T3/pl unknown
- 2015-07-17 SM SM20200715T patent/SMT202000715T1/it unknown
- 2015-07-17 CA CA2991750A patent/CA2991750C/en active Active
- 2015-07-17 ES ES20199208T patent/ES2987090T3/es active Active
- 2015-07-17 HR HRP20241154TT patent/HRP20241154T1/hr unknown
- 2015-07-17 LT LTEP20199208.8T patent/LT3821912T/lt unknown
- 2015-07-17 DK DK20199208.8T patent/DK3821912T3/da active
- 2015-07-17 HU HUE20199208A patent/HUE068183T2/hu unknown
- 2015-07-17 HR HRP20202023TT patent/HRP20202023T1/hr unknown
- 2015-07-17 CN CN201580051512.3A patent/CN107206105A/zh active Pending
- 2015-07-17 ES ES15825383T patent/ES2834402T3/es active Active
- 2015-07-17 RS RS20240901A patent/RS65909B1/sr unknown
- 2015-07-17 WO PCT/US2015/040866 patent/WO2016014353A1/en not_active Ceased
-
2019
- 2019-06-10 US US16/436,521 patent/US11045558B2/en active Active
- 2019-12-26 JP JP2019235539A patent/JP6966532B2/ja active Active
-
2021
- 2021-01-05 CY CY20211100002T patent/CY1123793T1/el unknown
- 2021-10-21 JP JP2021172128A patent/JP7198329B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123793T1 (el) | Γονιδιακη θεραπεια rpgr για μελαγχρωστικη αμφιβληστροειδοπαθεια | |
| CY1124588T1 (el) | Γενετικο κατασκευασμα | |
| SA518400623B1 (ar) | جينات ديستروفين صغير محسنة ومجموعات إظهارها واستخدامها | |
| HUE055002T2 (hu) | Nukleinsav-konstrukciók és génterápiás vektorok Wilson-kór kezelésében történõ alkalmazásra | |
| PH12018500964A1 (en) | Modified friedreich ataxia genes and vectors for gene therapy | |
| EP3645021A4 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | |
| MX392028B (es) | Vacunas para el tratamiento y prevención del cáncer. | |
| BR112017025045A2 (pt) | plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600 | |
| EP3138508C0 (en) | SURGICAL STAPLES INCLUDING VARIATIONS IN ITS HARDNESS TO IMPROVE TISSUE FIXATION | |
| ECSP16083000A (es) | Terapia genica para la retinitis pigmentaria | |
| CY1120772T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| MX387280B (es) | Sistema para la producción dirigida de una proteína terapéutica dentro de una célula objetivo y uso del sistema. | |
| SI3233129T1 (sl) | Konstrukti nukleinske kisline in vektorji genske terapije za uporabo pri zdravljenju Wilsonove bolezni in drugih stanj | |
| BR112018011838A2 (pt) | terapia gênica para distúrbios oculares | |
| EA201591839A1 (ru) | Терапевтические пептиды | |
| EP3484520A4 (en) | STABILIZING EXCIPIENTS FOR THERAPEUTIC PROTEIN FORMULATIONS | |
| AU2014375637A1 (en) | Formula of neuregulin preparation | |
| PL3340973T3 (pl) | Farmaceutycznie dopuszczalne sole kwasu beta-guanidynopropionowego o ulepszonych właściwościach, i ich zastosowania | |
| BR112016026245A2 (pt) | ?roedor, e, métodos para fazer um roedor humanizado, para fazer um camundongo com dpp4 humanizado, para fazer um roedor transgênico humanizado e para determinar a eficácia terapêutica in vivo de um antagonista da dpp4 específica para humanos no roedor? | |
| IL269483A (en) | Native cell derived vesicles containing tumor suppressor proteins for therapy | |
| IL265942A (en) | A nucleotide sequence expressing an exosome anchor protein for use as a component | |
| EA201890274A1 (ru) | Векторная система из аденовируса 9 птиц (fadv-9) и связанные способы | |
| EP4082445A4 (en) | INTEGRATED SYSTEM FOR CELL-FREE INTRACRANIAL DELIVERY | |
| IL274363B1 (en) | Use of a specific anti-protein siRNA for the treatment of hemophilia | |
| EP3717024C0 (en) | GENE THERAPY FOR IMPROVING EYE FUNCTION |